Clinical and Immunologic Efficacy of the Recombinant Adenovirus Type-5-Vectored (CanSino Bio) Vaccine in University Professors during the COVID-19 Delta Wave

Information regarding the efficacy of the recombinant adenovirus type-5-vectored (CanSino Bio) vaccine against the COVID-19 disease in a real-life setting is limited. A retrospective cohort study was carried out in the teaching university community of the metropolitan area of Monterrey, Mexico, thro...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2022-04, Vol.10 (5), p.656
Main Authors: Guzmán-López, Santos, Darwich-Salazar, Armine, Bocanegra-Ibarias, Paola, Salas-Treviño, Daniel, Flores-Treviño, Samantha, Pérez-Alba, Eduardo, Nuzzolo-Shihadeh, Laura M, Pérez-Rodríguez, Edelmiro, Camacho-Ortiz, Adrián
Format: Article
Language:English
Subjects:
adenovirus vector vaccine
Adenoviruses
Antibodies
Coronaviruses
COVID 19
COVID-19 vaccines
Drug dosages
Ethics
immunity
Immunoglobulin G
Infections
Mechanical ventilation
Medical research
Metropolitan areas
Proteins
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Statistical analysis
vaccine
Vaccines
Viral diseases
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Information regarding the efficacy of the recombinant adenovirus type-5-vectored (CanSino Bio) vaccine against the COVID-19 disease in a real-life setting is limited. A retrospective cohort study was carried out in the teaching university community of the metropolitan area of Monterrey, Mexico, through a four-section survey, and during the COVID-19 delta wave. Determination of IgG antibodies against SARS-CoV-2 spike (S) protein was performed in a subset of participants vaccinated with CanSino Bio. A total of 7468 teachers responded to the survey, and 6695 of them were fully vaccinated. Of those, 72.7% had CanSino Bio, 10.3% Pfizer, 8.4% AstraZeneca, 1.2% Moderna, and 2.7% others. Symptomatic breakthrough infections were recorded in those vaccinated with CanSino Bio (4.1%), AstraZeneca (2.1%), and Pfizer (2.2%). No difference was found between CanSino Bio and other vaccines regarding hospitalization, the need for mechanical ventilation, and death. For CanSino Bio recipients, anti-S antibodies were >50 AU/mL in 73.2%. In conclusion, primary breakthrough symptomatic infections were higher in the CanSino vaccinated group compared to other brands. Individuals with a previous infection had higher antibody levels than those who were reinfected and without infection. A boosted dose of CanSino is recommended for those individuals without a previous infection.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10050656